Case Report · Fallbericht
A Single Dose of Recombinant Activated Factor VII (NovoSeven®) Did Not Impair the Function of the Coronary Artery Bypass Grafts – Successful Treatment of Critical Bleeding after Cardiac Surgery in Two CasesPfau G.a · Schilling T.a · Kozian A.a · Huth C.b · Schneemilch C.E.a · Heim M.U.c
aDepartment of Anaesthesiology and Intensive Care Medicine, bDepartment of Cardiovascular and Thoracic Surgery, cInstitute of Transfusion Medicine and Immunohaematology, Otto-von-Guericke-University Magdeburg, Germany
Do you have an account?
Bleeding disorders and hemorrhages cause considerable morbidity and mortality in cardiac surgical patients. Possible thromboembolic complications make the use of recombinant activated factor VII (rFVIIa) in the treatment of bleeding after cardiac surgery controversial. Case Reports: We describe 2 patients who experienced intractable bleeding after open heart surgery with the use of cardiopulmonary bypass. Bleeding was successfully treated by a single dose (90 γg/kg) of rFVIIa without affecting the patency of the grafts. Conclusion: rFVIIa may provide an opportunity for an effective treatment of serious bleeding episodes both during cardiac surgery and in the postoperative course.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.